kidneys 3: 201
ureter 3: 221
urethra 3: 221
urinary system 3: 172
vesicoureteral reflux 3: 229
urine tests 4:314, 322, 350
urolithiasis 3:173, 184, 189, 196,
197 , 227–228, 229
urticaria 1: 183 , 205–206; 2:241,
269, 295; 4: 148
US Centers for Disease Control and
Prevention (CDC) 2:219, 299;
3:245, 246
alternative and complementary
approaches to conventional
medicine 4: 52
antibiotic resistance 4: 151
antismoking efforts 4: 8
childhood obesity 4: 291
fitness: exercise and health
4: 212
food safety 4: 24
HIV/AIDS prevention 4: 33
influenza 4: 36
sexually transmitted disease
prevention 4: 47
US Congress 4:83, 270
US Department of Agriculture
(USDA) 4:24, 186, 194–196
US Environmental Protection
Agency (EPA)
berylliosis 2: 192
building-related illness 4:12–13
drinking water standards 4: 19
heavy-metal poisoning 4: 30
indoor air quality 4: 34
lung cancer 2: 212
omega fatty acids and
cardiovascular health 2: 90
radon exposure 4: 43
sick building syndrome 4: 47
US Food and Drug Administration
(FDA) 2:159, 288, 368, 373;
3: 264
adverse drug reaction 4: 149
Alzheimer’s disease 1: 222
antibiotic resistance 4: 151
bioequivalence 4: 153
birth defects 4: 9
botulinum therapy 1: 141
drinking water standards
4:19–21
drugs 4: 146
food safety 4: 24
generic drug 4: 158
HIV/AIDS prevention 4: 33
homeopathy 4: 75
imported drug 4: 159
IND 4:159–160
innovator drug 4: 159
keratoconus 1: 99
magnet therapy 4: 81
medicinal herbs and botanicals
4: 84
meninges 1: 263
myopia 1: 101
nutritional supplements 4: 196
off label use 4: 163
Orange Book, The4: 163
OTC drug 4: 167
outdated drug 4: 164
Parkinson’s disease 1: 276
pharmacopeia 4: 169
soy 4: 98
therapeutic equivalence 4: 172
yohimbe 4: 107
US National Institutes of Health
(NIH) 1:141, 365; 4:56, 300
US Occupational Safety and Health
Administration (OSHA) 1:30, 37;
2:183, 192, 207, 229, 230; 4: 24
US Surgeon General 4:210, 282,
283, 335–336
uterine fibroids 3:277, 338, 349–350
uterine prolapse 3: 338 , 350–351
uterus 3:351, 351 t
D&C 3: 268
DUB 3: 268
endometrial hyperplasia 3: 275
endometriosis 3: 276
hysteroscopy 3: 292
pregnancy 3: 322
progesterone 3: 156
semen 3: 337
sperm 3: 342
tubal ligation 3: 347
uterine fibroids 3: 349
uterine prolapse 3: 350
UTI. Seeurinary tract infection
uveitis 1: 97 , 120
uvula 1:5, 16V
vaccination 1:277; 4:17, 35, 42
vaccine 2:298–299, 298 t–299t
active immunity 2: 239
antibody 2: 245
cancer vaccines 2:373
childhood diseases 4: 17
heavy-metal poisoning 4: 31
HIV/AIDS prevention 4: 32
immune system 2: 237immunization 2: 338
immunotherapy 2: 277
infectious diseases 2:304, 305
preventive medicine 4: 1
VACTERL 2:37–38, 40; 3:352
VADs. Seeventricular assist devices
vagina 3:352–353, 353 t
Bartholin’s cyst 3: 248
genital herpes 2: 328
gonnorhea 2: 330
HPV 2:336, 337
pelvic examination 3: 316
rectal fistula 3: 86
rectocele 3: 87
semen 3: 337
uterine prolapse 3: 350
vaginal birth 3:261, 355
vaginal birth after cesarean. See
VBAC
vaginitis 2:311, 315, 347, 358;
3: 248 , 353
vagus nerve 1:53, 246; 3:52, 94
valerian 4:62, 89, 99, 104, 104 t
valley fever. Seecoccidioidomycosis
valproic acid (valporate) 3:367,
377, 386
VA LT. Seevascular-associated
lymphoid tissue
valvular heart disease 2:51, 54, 55,
59, 60, 103, 113–114, 113 t
variable pain response 1:388
variation 4:143–144
varicella disease. Seechickenpox
varicella zoster 1:103, 269; 2:221,
315, 316, 332
varicocele 3: 346 , 353–354
varicose veins 2: 48 , 114–115,115,
225
vascular-associated lymphoid tissue
(VALT) 2: 284 , 299
vasculitis 1:117; 2: 200 t, 249 t,
299–302, 300 t–301t
vas deferens 3:222, 277, 343, 346,
354, 354
vasectomy 3:281, 337, 354,
354–355
vasoconstrictors 2:83, 86t,101,
230; 4:345, 353
vasodilators 2:83–84, 84t, 86 t, 99
VBAC (vaginal birth after cesarean)
3:261, 262, 355
vein 2:115; 4: 362
AVM 2:19–20
blood vessels 2:4–5
cardiovascular system 2: 6
circulation 2: 5Index 511